CN105111305B - 酰化胰岛素的色谱纯化方法 - Google Patents
酰化胰岛素的色谱纯化方法 Download PDFInfo
- Publication number
- CN105111305B CN105111305B CN201510651298.7A CN201510651298A CN105111305B CN 105111305 B CN105111305 B CN 105111305B CN 201510651298 A CN201510651298 A CN 201510651298A CN 105111305 B CN105111305 B CN 105111305B
- Authority
- CN
- China
- Prior art keywords
- phase
- chromatographic
- insulin
- chromatographic purification
- purification method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims abstract description 72
- 238000011097 chromatography purification Methods 0.000 title claims abstract description 48
- 239000000945 filler Substances 0.000 claims abstract description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 28
- 239000000741 silica gel Substances 0.000 claims abstract description 28
- 238000010828 elution Methods 0.000 claims description 44
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 26
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000011068 loading method Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- -1 fatty acid ester Chemical class 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000010829 isocratic elution Methods 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 235000021314 Palmitic acid Nutrition 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
- 229910021538 borax Inorganic materials 0.000 claims description 3
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 claims description 3
- 239000004328 sodium tetraborate Substances 0.000 claims description 3
- NZEDHZOVUDEBGW-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O NZEDHZOVUDEBGW-UHFFFAOYSA-N 0.000 claims description 2
- 239000012043 crude product Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- PEJVSXYBFAVPAQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) octanoate Chemical compound CCCCCCCC(=O)ON1C(=O)CCC1=O PEJVSXYBFAVPAQ-UHFFFAOYSA-N 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 45
- 230000008569 process Effects 0.000 abstract description 15
- 239000004026 insulin derivative Substances 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 7
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract description 6
- 230000003321 amplification Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 229960001866 silicon dioxide Drugs 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 76
- 239000000523 sample Substances 0.000 description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 238000012856 packing Methods 0.000 description 18
- 239000012521 purified sample Substances 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000003446 ligand Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 229920000620 organic polymer Polymers 0.000 description 6
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000005580 one pot reaction Methods 0.000 description 5
- WSXGQYDHJZKQQB-UHFFFAOYSA-N 3-pyridin-4-ylpropanoic acid Chemical compound OC(=O)CCC1=CC=NC=C1 WSXGQYDHJZKQQB-UHFFFAOYSA-N 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 238000006481 deamination reaction Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000004237 preparative chromatography Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010089308 Insulin Detemir Proteins 0.000 description 2
- 229910008051 Si-OH Inorganic materials 0.000 description 2
- 229910006358 Si—OH Inorganic materials 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229960003948 insulin detemir Drugs 0.000 description 2
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- RPDKBNDLAVNLSQ-UHFFFAOYSA-L [Na+].[Na+].CC#N.[O-]S([O-])(=O)=O Chemical compound [Na+].[Na+].CC#N.[O-]S([O-])(=O)=O RPDKBNDLAVNLSQ-UHFFFAOYSA-L 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510651298.7A CN105111305B (zh) | 2015-10-10 | 2015-10-10 | 酰化胰岛素的色谱纯化方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510651298.7A CN105111305B (zh) | 2015-10-10 | 2015-10-10 | 酰化胰岛素的色谱纯化方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105111305A CN105111305A (zh) | 2015-12-02 |
| CN105111305B true CN105111305B (zh) | 2018-12-14 |
Family
ID=54659450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510651298.7A Active CN105111305B (zh) | 2015-10-10 | 2015-10-10 | 酰化胰岛素的色谱纯化方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105111305B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112341536A (zh) * | 2019-08-07 | 2021-02-09 | 中国科学院大连化学物理研究所 | 一种高效液相色谱技术纯化制备胰岛素的方法 |
| CN112341535A (zh) * | 2019-08-07 | 2021-02-09 | 中国科学院大连化学物理研究所 | 一种采用离子交换色谱法分离纯化制备胰岛素的方法 |
| CN111778231A (zh) * | 2020-07-29 | 2020-10-16 | 珠海冀百康生物科技有限公司 | 一种赖氨酰肽链内切酶的纯化方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1171742A (zh) * | 1994-11-17 | 1998-01-28 | 伊莱利利公司 | ε-氨基的选择性酰化 |
| CN1313866A (zh) * | 1998-08-24 | 2001-09-19 | 阿文蒂斯药物德国有限公司 | 色谱纯化胰岛素的方法 |
| CN102471368A (zh) * | 2009-08-11 | 2012-05-23 | 拜康有限公司 | 色谱方法及其纯化的化合物 |
-
2015
- 2015-10-10 CN CN201510651298.7A patent/CN105111305B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1171742A (zh) * | 1994-11-17 | 1998-01-28 | 伊莱利利公司 | ε-氨基的选择性酰化 |
| CN1313866A (zh) * | 1998-08-24 | 2001-09-19 | 阿文蒂斯药物德国有限公司 | 色谱纯化胰岛素的方法 |
| CN102471368A (zh) * | 2009-08-11 | 2012-05-23 | 拜康有限公司 | 色谱方法及其纯化的化合物 |
Non-Patent Citations (2)
| Title |
|---|
| Process and purification for manufacture of a modified insulin intended for oral delivery;Nitesh Dave等;《Journal of Chromatography A》;20070722;第1177卷(第2期);第282页左栏第2段,右栏第1-2段,第283页第2.1.1.1和2.2.3小节,第284页表2 * |
| 重组胰岛素前体转化成人胰岛素和地特胰岛素的工艺研究;刘海峰;《中国博士学位论文全文数据库工程科技I辑》;20140615(第6期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105111305A (zh) | 2015-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105111305B (zh) | 酰化胰岛素的色谱纯化方法 | |
| CN102947327B (zh) | 卡泊芬净中间体的纯化 | |
| CN114660214B (zh) | 一种司美格鲁肽的液相色谱检测方法及其应用 | |
| Xiong et al. | Preparation and evaluation of a hydrophilic interaction and cation-exchange chromatography stationary phase modified with 2-methacryloyloxyethyl phosphorylcholine | |
| CN113544137B (zh) | 一种万古霉素类似物的分离纯化方法 | |
| US9724622B2 (en) | Purification of organic compounds using surrogate stationary phases on reversed phase columns | |
| EP3009429B1 (en) | R type resveratrol dimer, preparation method therefor and use thereof in reducing blood sugar | |
| AU2004221834B2 (en) | Purification of taxanes and taxane mixtures using polyethyleneimine-bonded resins | |
| Wang et al. | Refolding and purification of recombinant human granulocyte colony-stimulating factor using hydrophobic interaction chromatography at a large scale | |
| CN106290601B (zh) | 多肽药物中氨基酸消旋和非对映异构体杂质的检测方法 | |
| CN106770849B (zh) | 一种测定度骨化醇及其所含杂质的检测方法 | |
| CN104081198B (zh) | 分离剂及其制造方法 | |
| CN106483202B (zh) | 一种分离和测定阿利维a酸与异构体的方法 | |
| CN103554221A (zh) | 一组蛇毒来源的活性肽的制备方法 | |
| CN113801201A (zh) | 一种醋酸卡泊芬净杂质b的制备方法 | |
| CN103113211A (zh) | 一种外消旋2-苯丙酸的拆分方法 | |
| CN105646429B (zh) | 一种制备高纯度儿茶素没食子酸酯cg的方法 | |
| CN100448859C (zh) | 使用键合有聚乙烯亚胺的树脂提纯紫杉醇和紫杉醇混合物的方法 | |
| CN109485616B (zh) | 一种依托度酸光降解杂质及其制备方法 | |
| JP7601795B2 (ja) | Glp-1類似体の精製 | |
| CN112341536A (zh) | 一种高效液相色谱技术纯化制备胰岛素的方法 | |
| Han et al. | Optimized separation of astaxanthin stereoisomers from microbial sources using chiral HPLC | |
| CN115536733A (zh) | 一种尿鸟苷蛋白类似物盐及片剂的制备方法 | |
| Patil et al. | Procedure for chromatography involving sample solvent with higher elution strength than the mobile phase | |
| CN113960195A (zh) | 一种尼麦角林中间体10α-甲氧基-二氢麦角醇的HPLC检测方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Shandong city of Liaocheng province Dong'e 252201 Jiao County Street No. 78 Co-patentee after: DONG-E E-JIAO Co.,Ltd. Patentee after: Huarun Onde Biopharmaceutical Co.,Ltd. Co-patentee after: EAST CHINA University OF SCIENCE AND TECHNOLOGY Address before: Shandong city of Liaocheng province Dong'e 252201 Jiao County Street No. 78 Co-patentee before: DONG-E E-JIAO Co.,Ltd. Patentee before: ANGDE BIOLOGY PHARMACEUTICAL CO.,LTD. Co-patentee before: EAST CHINA University OF SCIENCE AND TECHNOLOGY Address after: Shandong city of Liaocheng province Dong'e 252201 Jiao County Street No. 78 Co-patentee after: DONG-E E-JIAO Co.,Ltd. Patentee after: ANGDE BIOLOGY PHARMACEUTICAL CO.,LTD. Co-patentee after: EAST CHINA University OF SCIENCE AND TECHNOLOGY Address before: Shandong city of Liaocheng province Dong'e 252201 Jiao County Street No. 78 Co-patentee before: DONG-E E-JIAO Co.,Ltd. Patentee before: SHANDONG EHUA BIOLOGICAL PHARMACEUTICAL Co.,Ltd. Co-patentee before: EAST CHINA University OF SCIENCE AND TECHNOLOGY |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210119 Address after: 252201, No. 78 donkey hide street, Dong'e County, Shandong, Liaocheng Patentee after: Huarun Onde Biopharmaceutical Co.,Ltd. Patentee after: EAST CHINA University OF SCIENCE AND TECHNOLOGY Address before: 252201, No. 78 donkey hide street, Dong'e County, Shandong, Liaocheng Patentee before: Huarun Onde Biopharmaceutical Co.,Ltd. Patentee before: Dong-e E-jiao Co.,Ltd. Patentee before: EAST CHINA University OF SCIENCE AND TECHNOLOGY |